title: Prevalence of diabetes and impaired glucose tolerance in adult hypopituitarism on low dose oral hydrocortisone replacement therapy.
abstract: OBJECTIVE
  The conventional dosage of hydrocortisone, used for many years in the management of hypopituitarism (30 mg per day), has now been shown to be more than is physiologically necessary. On this conventional corticosteroid therapy studies have demonstrated an increased prevalence of diabetes and impaired glucose tolerance, which may contribute to the increased vascular morbidity and mortality reported in the condition. In these studies no information is available on oral glucose tolerance test (OGTT) timing in relation to administration of oral steroid and variable hydrocortisone doses were employed.
  
  
  METHODS
  In order to assess glucose tolerance in patients treated with lower, more physiological doses, we performed a 75-g OGTT at least 1 month after hydrocortisone therapy was adjusted to 15 mg at 0800 h and 5 mg at 1700 h in 45 adult onset hypopituitary patients (30 M, 15 F). Mean (+/- SD) duration of hypopituitarism was 12 +/- 10 years, mean age 52 +/- 14 years and BMI 29.3 +/- 5.1 kg/m2. All were on hydrocortisone, 43 on thyroxine, 31 on sex steroids, 9 on desmopressin and 33 had documented growth hormone deficiency. Hydrocortisone 15 mg was taken at 0800 and the OGTT commenced at 0900.
  
  
  RESULTS
  Using standard WHO criteria 36 patients (80%) had normal glucose tolerance, 1 (2%) had newly diagnosed diabetes and 8 (18%) had impaired glucose tolerance. Using the recently announced American Diabetes Association criteria for diagnosis 96% had normal glucose tolerance, 2% had diabetes and 2% impaired fasting glucose.
  
  
  CONCLUSIONS
  The markedly reduced prevalence of diabetes and impaired glucose tolerance on lower hydrocortisone replacement doses in our series of patients with hypopituitarism, not previously known to be diabetic, is of great interest. This lower prevalence may eventually result in reduced vascular complication rates.
authors.affiliation: Metabolic Unit, Royal Victoria Hospital, Grosvenor Road, Belfast, BT12 6BA, Northern Ireland, UK.
authors.forename: E M
authors.initials: EM
authors.lastname: McConnell
authors.forename: P M
authors.initials: PM
authors.lastname: Bell
authors.forename: D R
authors.initials: DR
authors.lastname: Hadden
authors.forename: D R
authors.initials: DR
authors.lastname: McCance
authors.forename: B
authors.initials: B
authors.lastname: Sheridan
authors.forename: A B
authors.initials: AB
authors.lastname: Atkinson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002096:C-Peptide / Q000097:blood; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000175:diagnosis*; D004334:Drug Administration Schedule; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D007018:Hypopituitarism / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric
chemical_list: D002096:C-Peptide; D007328:Insulin; D006854:Hydrocortisone